Connect Biopharma Holdings EBIT

Connect Biopharma Holdings (CNTB) currently reports a EBIT of $-99M as of June 2026. That compares with $-32M in the prior-year period — down 205.1% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Connect Biopharma Holdings's EBIT history and peer comparisons.

Connect Biopharma Holdings's EBIT decreased from $-32M to $-99M — a 205.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Connect Biopharma Holdings's EBIT of $-99M is lower than the Healthcare sector average of $110B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Connect Biopharma Holdings reported $-99M in EBIT as of June 2026. That compares with $-32M in the prior-year period — down 205.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-99M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Connect Biopharma Holdings, and consider following CNTB for alerts when major investors trade the stock.